 |
Gyan Bhanot, PhD Dr. Bhanot's current research interests are is in the area of Translational Medicine and Evolutionary Biology, particularly working on developing methods to improve chemotherapy outcome, optimize immune checkpoint therapy, and understand the role of the ribosome in evolution. |
 |
Chang S. Chan, PhD Dr. Chan’s lab is interested in understanding the role of p53 in cancer, and focuses on cancer genomics, cancer evolution and resistance to therapy, and gene regulation. |
 |
Subhajyoti De, PhD Dr. De’s lab develops and employs computational genomics tools to understand the biology of cancer and apply that knowledge to improve early detection, stratification, and therapeutic opportunities for patients. The interests of the lab include single molecule sequencing, evolutionary dynamics of tumor, genomic instability, and non-coding mutations in cancer. |
 |
David J. Foran, PhD Dr. Foran's lab designs, develops, and implements new approaches in computational imaging, statistical pattern recognition, and computer-based diagnostics for resolving challenging problems in oncology / pathology / radiology. |
 |
Shridar Ganesan, MD, PhD Dr. Ganesan’s lab studies DNA repair mechanisms and chromatin biology, the role of BRCA1 and 53BP1 in DNA repair, tumorigenesis and chemosensitivity, and genomic classification of human cancer. |
 |
Michael L. Gatza, PhD Dr. Gatza’s lab leverages cancer genomics and bioinformatics with experimental molecular biology and genetics to identify and elucidate mechanisms of oncogenic signaling and cancer genesis as a means to further understand breast and ovarian tumor biology and to develop personalized cancer therapies. |
 |
Daniel Herranz Benito, PharmD, PhD Dr. Herranz’s lab is is focused on discovering and defining how oncogenic and tumor suppressor enhancers impact tumorigenesis in hematological and solid tumors. The lab also works on dissecting the interplay between cancer cell-specific metabolic rewiring and epigenetics in T-cell Acute Lymphoblastic Leukemia (T-ALL). |
 |
Hossein Khiabanian, PhD Dr. Khiabanian’s lab develops mathematical methods and employs high-throughput genomics techniques to understand the underlying genetics of human malignancies, especially to study the evolution of clonal expansions in the context of disease transformation and relapse. |
 |
Greg M. Riedlinger, MD, PhD Dr. Riedlinger’s research interests are in employing next-generation sequencing for molecular oncology, and developing pathology informatics tools for personalized medicine. |
 |
Jeffrey A. Rosenfeld, PhD Dr. Rosenfeld is the Manager of the Biomedical Informatics Shared Resource. His research focuses on the use of new genomics technologies to solve long-standing problems in cancer and other diseases. |
 |
Bin Tian, PhD Dr. Tian’s lab studies RNA biology using molecular systems biology approaches. Currently, we are investigating mechanisms and consequences of alternative cleavage and polyadenylation (APA) in differentiation, development and cancer. |
 |
Michael P. Verzi, PhD Dr. Verzi’s lab uses epigenomic approaches to understand how transcriptional regulatory mechanisms contribute to intestinal development and disease, particularly in how tumor suppressor transcription factors interact with tumor chromatin to control progression of colorectal cancer. |
 |
William J. Welsh, PhD Dr. Welsh’s lab is interested in drug discovery, chemical informatics, predictive toxicology, medicinal chemistry, rational drug design, pattern recognition, and data mining tools. |
